期刊
EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 20, 期 6, 页码 627-641出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737175.2020.1772758
关键词
Migraine; Calcitonin Gene-Related Peptide; GCRP; erenumab; galcanezumab; fremanezumab; eptinezumab; atogepant; rimegepant; ubrogepant
Introduction Calcitonin Gene-Related Peptide (CGRP) has gradually emerged as a suitable therapeutic target to treat migraine. Considering the social and economic burden of migraine, it is fundamental to optimize the disease management with efficacious and safe treatments. In this scenario, drugs targeting GCRP, monoclonal antibodies (MoAbs) and gepants, represent new therapeutic strategies. Areas covered In the present work, the authors aim at appraising the main insights and implications of those treatments targeting CGRP by reviewing pathophysiology and clinical information. Expert opinion Anti-CGRP MoAbs are the first migraine-specific preventive treatments representing a suitable option especially for difficult-to-treat patients. They can be safely administered for long periods even in association with preventatives acting on different targets. Gepants are a safe alternative to triptans for the acute management of migraine and are currently being tested for prevention, thus representing the first transitional molecules for disease therapy. In the future, it might be possible to adapt the treatment according to patients' characteristics and disease phenotype even combining the two treatments targeting the CGRP pathway.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据